Eutilex.Co.Ltd (KQ:263050) — Market Cap & Net Worth
Market Cap & Net Worth: Eutilex.Co.Ltd (263050)
Eutilex.Co.Ltd (KQ:263050) has a market capitalization of $23.94 Million (₩35.32 Billion) as of May 5, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #24464 globally and #1805 in its home market, demonstrating a 29.59% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Eutilex.Co.Ltd's stock price ₩959.00 by its total outstanding shares 36830878 (36.83 Million). Analyse 263050 cash generation efficiency to see how efficiently the company converts income to cash.
Eutilex.Co.Ltd Market Cap History: 2018 to 2026
Eutilex.Co.Ltd's market capitalization history from 2018 to 2026. Data shows change from $661.06 Million to $23.94 Million (-35.31% CAGR).
Index Memberships
Eutilex.Co.Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$306.89 Billion | 0.01% | #969 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$306.89 Billion | 0.01% | #969 of 1384 |
Weight: Eutilex.Co.Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Eutilex.Co.Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Eutilex.Co.Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.01x
Eutilex.Co.Ltd's market cap is 0.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $661.06 Million | $402.03 Million | -$13.23 Billion | 1.64x | N/A |
| 2019 | $511.37 Million | $408.88 Million | -$17.13 Billion | 1.25x | N/A |
| 2020 | $571.40 Million | $2.04 Billion | -$28.77 Billion | 0.28x | N/A |
| 2021 | $339.65 Million | $73.54 Million | -$29.89 Billion | 4.62x | N/A |
| 2022 | $165.73 Million | $215.66 Million | -$33.43 Billion | 0.77x | N/A |
| 2023 | $84.36 Million | $131.65 Million | -$27.72 Billion | 0.64x | N/A |
| 2024 | $48.02 Million | $9.53 Billion | -$29.17 Billion | 0.01x | N/A |
Competitor Companies of 263050 by Market Capitalization
Companies near Eutilex.Co.Ltd in the global market cap rankings as of May 5, 2026.
Key companies related to Eutilex.Co.Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $109.06 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #357 globally with a market cap of $73.69 Billion USD.
- UCB SA (BR:UCB): Ranked #519 globally with a market cap of $50.85 Billion USD ( €43.50 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #567 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $109.06 Billion | $429.85 |
| #357 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.69 Billion | $709.21 |
| #519 | UCB SA | BR:UCB | $50.85 Billion | €228.50 |
| #567 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Eutilex.Co.Ltd Historical Marketcap From 2018 to 2026
Between 2018 and today, Eutilex.Co.Ltd's market cap moved from $661.06 Million to $ 23.94 Million, with a yearly change of -35.31%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩23.94 Million | -13.45% |
| 2025 | ₩27.66 Million | -42.41% |
| 2024 | ₩48.02 Million | -43.08% |
| 2023 | ₩84.36 Million | -49.10% |
| 2022 | ₩165.73 Million | -51.20% |
| 2021 | ₩339.65 Million | -40.56% |
| 2020 | ₩571.40 Million | +11.74% |
| 2019 | ₩511.37 Million | -22.64% |
| 2018 | ₩661.06 Million | -- |
End of Day Market Cap According to Different Sources
On May 5th, 2026 the market cap of Eutilex.Co.Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $23.94 Million USD |
| MoneyControl | $23.94 Million USD |
| MarketWatch | $23.94 Million USD |
| marketcap.company | $23.94 Million USD |
| Reuters | $23.94 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Eutilex.Co.Ltd
Eutilex.Co.,Ltd. engages in the discovery and development of immunomodulatory antibody therapeutics to treat cancers and autoimmune diseases. It develops EU101, a fully humanized anti-human 4-1BB monoclonal antibody; EU103, a fully humanized therapeutic monoclonal antibody; and EU501, an 4-1BB mAb-based, tumor antigen targeting bispecific antibodies. The company was founded in 2008 and is headqua… Read more